Healthcare - Biotechnology - NASDAQ - US
$ 1.77
-8.29 %
$ 78.9 M
Market Cap
-1.16
P/E
CASH FLOW STATEMENT
-32.6 M
OPERATING CASH FLOW
-769 K
INVESTING CASH FLOW
58.4 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Werewolf Therapeutics, Inc.
| Net Income | -37.4 M |
| Depreciation & Amortization | 1.76 M |
| Capital Expenditures | -769 K |
| Stock-Based Compensation | 8.01 M |
| Change in Working Capital | -5.89 M |
| Others | -6.26 M |
| Free Cash Flow | -33.4 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (37.4) | (53.8) | (50.0) | (15.0) | (10.2) |
| Depreciation & Amortization | 1.8 | 1.1 | 0.2 | 0.1 | 25 K |
| Deferred Income Tax | 0 | 0 | 0 | (7.3) | (0.1) |
| Stock Based Compensation | 8.0 | 7.4 | 4.1 | 0.6 | 0.6 |
| Other Operating Activities | 0.9 | 2.2 | 0.5 | 0.6 | 0.9 |
| Change in Working Capital | (5.9) | 2.5 | 2.3 | 2.3 | (0.7) |
| Cash From Operations | (32.6) | (40.6) | (42.9) | (18.6) | (9.5) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (0.8) | (3.6) | (0.5) | (0.6) | (0.3) |
| Other Items | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (0.8) | (3.6) | (0.5) | (0.6) | (0.3) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 40.0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 100 K | 0.2 | (2.2) | 94.0 | 21.9 |
| Cash From Financing Activities | 58.4 | 15.9 | 109.4 | 93.9 | 21.9 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 25.0 | (28.3) | 66.1 | 74.7 | 12.1 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (33.4) | (44.2) | (43.4) | (19.2) | (9.8) |